NILK-2401
CEA-positive solid tumors
Key Facts
About Light Chain Bioscience
Light Chain Bioscience is a private, clinical-stage biotech advancing a pipeline of bispecific antibodies using its proprietary Kλ body technology. Its lead programs target CD47 in a tumor-restricted manner to overcome historical safety challenges, with one asset in Phase II and several others in Phase I/II development. The company operates a partnership-driven business model, co-developing assets with partners like LamKap Bio, and is positioned in the competitive but high-potential bispecific antibody and CD47-targeting therapeutic space.
View full company profileAbout LamKap Bio
LamKap Bio is a private, preclinical-stage biotech developing a pipeline of bispecific antibodies targeting solid tumors. Its core technology is the κλ-body platform, which enables the creation of fully human, multispecific antibodies designed to be 'truly natural' to potentially improve safety and efficacy. The company's most advanced program, NILK-2301 (CEA x CD3), has entered Phase 1 clinical trials, positioning it as an emerging player in the competitive T-cell engager and macrophage-redirection space for oncology.
View full company profileTherapeutic Areas
Other CEA-positive solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NILK-2301 | Light Chain Bioscience | Phase I |